Long-term improvement of fasting glycaemia after switching basal insulin from NPH to determir in children with type 1 diabetes: A 1-year multicentre study;Změna bazálního inzulínu z NPH na inzulínový analog detemir vede k dlouhodobému zlepšení ranní glykémie nalačno u dětí s diabetes mellitus 1. typu: Výsledky roční multicentrické studie

Casopis Lekaru Ceskych

Volumn 147, Issue 8, 2008, Pages 421-425

  Šumník, Zdeněk ^a   Venhacova J ^b   Brazdova L ^c   Skvor J ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c Nemocnice Milosrdných Bratří ^*

Author keywords

Children; Detemir; Insulin analogues; NPH insulin; Type 1 diabetes

Indexed keywords

BASAL INSULIN; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN DETEMIR; ISOPHANE INSULIN;

ADOLESCENT; ARTICLE; BLOOD; CHILD; CLINICAL TRIAL; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MULTICENTER STUDY; PRESCHOOL CHILD;

ADOLESCENT; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFANT; INSULIN; INSULIN, ISOPHANE; MALE;

EID: 52449111542     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. The DCCT research group: Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J. Pediatr., 1994, 125, s. 177-188.
2. Danne, T., Mortensen, H. B., Ougaard, P. et al.: Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidore Study Group. Diabetes Care, 2001, 24, s. 1342-1347.
3. Cinek, O., Šumník, Z., Vavřinec, J.: Dětský diabetes mellitus v České republice: stále více a čím dál dříve. Čas. Lék. čes., 2005, 144, s. 266-271.
4. Kurtzhals, P.: Pharmacology of insulin detemir. Endocrinol. Metab. Clin. North. Am., 2007, 36 (Suppl. 1), s. 14-20.
5. Chapman, T. M., Perry, C. M.: Insulin Detemir. A Review of its use in the management of type 1 and 2 diabetes mellitus. Drugs, 2004, 64, s. 2577-2595.
6. Holleman, F., Gale, E. A.: Nice insulins, pity about the evidence. Diabetologia, 2007, 50, s. 1783-1790.
7. Robertson, K. J., Schoenle, E., Gucev, Z. et al.: Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet. Med., 2007, 24, s. 27-34.
8. Haladová, I., Lacigová, S., Jankovec, Z. et al.: Klinické zkušenosti s léčbou dlouhodobým inzulinovým analogem glargin v diabetologickém centru. Vnitř. Lék., 2007, 53, s. 632-636.
9. Gough, S. C.: A review of human and analogue insulin trials. Diabetes Res. Clin. Pract, 2007, 77, s. 1-15.
10. Heise, T., Nosek, L., Rønn, B. B., et al.: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes, 2004, 53, s. 1614-1620.
11. Vague, P., Selam, J. L., Skeie, S. et al.: Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care, 2003, 26, s. 590-596.
12. Danne, T., Lüpke, K., Walte, K. et al.: Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabe-tes. Diabetes Care, 2003, 26, s. 3087-3092.
13. Home, P., Bartley, P., Russell-Jones, D. et al.: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care, 2004, 27, s. 1081-1087.
14. Pieber, T. R., Draeger, E., Kristensen, A. et al.: Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet. Med., 2005, 22, s. 850-857.
15. Standl, E., Lang, H., Roberts, A.: The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol. Then, 2004, 6, s. 579-588.
16. Doyle, E. A., Weinzimer, S. A., Steifen, A. T. et al.: A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care, 2004, 27, s. 1554-1558.
17. Braunholtz, D. A., Edwards, S. J., Lilford, R. J.: Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J. Clin. Epidemiol., 2001, 54, s. 217-224.
18. Martin, D. D., Davis, E. A., Jones, T. W.: Acute effects of hyperglycaemia in children with type 1 diabetes mellitus: the patient's perspective. J. Pediatr. Endocrinol. Metab., 2006, 19, s. 927-936.
19. Reinehr, T., Holl, R. W., Roth, C. L. et al.: Insulin resistance in children and adolescents with type 1 diabetes mellitus: relation to obesity. Pediatr. Diabetes, 2005, 6, s. 5-12.